Table 2 Particular characteristics of HIV-HCV coinfected patients according to RBV AUC 0-4h threshold (n = 23)
All (n = 23) | RBV AUC 0-4h<1755 μg.h/L (n = 14) | RBV AUC 0-4h>1755 μg.h/L (n = 9) | p value | |
|---|---|---|---|---|
HIV RNA <50 copies/mL, n (%) | 20 (87) | 11 (79) | 9 (100) | 0.253 |
HIV RNA copies/mL | 50 (20–9850) | 50 (20–9850) | 50 (40–50) | 0.687 |
CD4 (cells/mm3) | 543 (325–1067) | 498 (325–993) | 543 (368–1067) | 0.614 |
CD4% | 30 (10–48) | 29.5 (10–48) | 32 (27–45) | 0.174 |
Duration of HIV treatment (years) | 11 (1–19) | 11 (1–16) | 10 (2–19) | 0.825 |
Antiretroviral therapy, n (%) | ||||
Protease inhibitor | 14 (61) | 7 (50) | 7 (78) | |
Nucleoside reverse transcriptase inhibitor (NRTI) | 21 (91) | 13 (93) | 8 (89) | |
Non-nucleoside reverse transcriptase inhibitor (NNRTI) | 8 (35) | 6 (43) | 2 (22) | |
Integrase inhibitor | 4 (17) | 1 (<1) | 3 (33) | |
Receptor CCR5 inhibitor | 1 (<1) | 0 | 1 (11) |